Maa: Uusi-Seelanti
Kieli: englanti
Lähde: Medsafe (Medicines Safety Authority)
Ciprofloxacin hydrochloride 291.08mg equivalent to ciprofloxacin base 250 mg;
REX Medical Ltd
Ciprofloxacin hydrochloride 291.08 mg (equivalent to ciprofloxacin base 250 mg)
250 mg
Film coated tablet
Active: Ciprofloxacin hydrochloride 291.08mg equivalent to ciprofloxacin base 250 mg Excipient: Colloidal silicon dioxide Croscarmellose sodium Hypromellose Purified talc Croscarmellose sodium Macrogol 6000 Magnesium stearate Microcrystalline cellulose Povidone Propylene glycol Purified talc Titanium dioxide
Blister pack, PVC/aluminium foil blisters, 30 tablets
Prescription
Prescription
Marksans Pharma Limited
Package - Contents - Shelf Life: Blister pack, PVC/aluminium foil blisters - 30 tablets - 36 months from date of manufacture stored at or below 25°C
2003-05-27
NEW ZEALAND DATASHEET NAME OF MEDICINE CIPROFLOXACIN Ciprofloxacin hydrochloride tablets PRESENTATION Ciprofloxacin tablets 250 mg: white, circular, biconvex, film-coated tablet, with a score and “CP 250” embossed on one side and plain on the other. Ciprofloxacin tablets 500 mg: white, capsule shaped, film-coated tablet, with a score and “CPX 500” embossed on one side and “NEO embossed on the other. Ciprofloxacin tablets 750 mg: white, capsule shaped, film- coated tablet, with “CPX 750” embossed on one side and “NEO embossed on the other. Do not halve the tablet. Dose equivalence when the tablet is divided has not been established. USES ACTIONS Ciprofloxacin is a synthetic broad spectrum antibacterial agent (ATCCODE: J 01 MA 02). MECHANISM OF ACTION Ciprofloxacin is effective in-vitro against a wide range of Gram-negative and Gram-positive organisms. The bactericidal action of ciprofloxacin results from inhibition of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), which are required for bacterial DNA replication, transcription, repair, and recombination. MECHANISM OF RESISTANCE _In vitro _resistance to ciprofloxacin is commonly due to mutations in bacterial topoisomerases and DNA gyrase through multiple-step mutations. Single mutations may result in reduced susceptibility rather than clinical resistance, but multiple mutations generally result in clinical resistance to ciprofloxacin and cross-resistance across the quinolone class. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common Lue koko asiakirja